THEMIS2 and colorectal carcinoma: We further divided the gene set according to the occurrence of mutations in oncodriver pathways identified in our previous exome studies as associated with CRC progression (MYC, Hippo, Notch, RTK-RAS, PI3K, HRR, and the immunogenic signature ICB1) [19] (Supplementary TableS5).